U.S. License Holder:
Coherus Biosciences / / Bioeq
Date of License:
CIMERLI (ranibizumab-eqrn), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
Neovascular (Wet) Age-Related Macular Degeneration (AMD);
Macular Edema Following Retinal Vein Occlusion (RVO);
Diabetic Macular Edema (DME);
Diabetic Retinopathy (DR);
Myopic Choroidal Neovascularization (mCNV).
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Ongavia (Teva / Bioeq) (May-2022 in the United Kingdom) Ranivisio (Teva / Bioeq) (August-2022)